After recognition, FH undergoes conformational changes and interacts with additional complement proteins such as factor I. This results in the inhibition of complement activation and contributes to the protection of the host cell against CML. This evidence concerns the gene FH and chronic myelogenous leukemia, BCR-ABL1 positive.